Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 24 04:00PM ET
6.63
Dollar change
+3.59
Percentage change
118.29
%
Index- P/E- EPS (ttm)-11.32 Insider Own- Shs Outstand1.44M Perf Week70.63%
Market Cap8.07M Forward P/E- EPS next Y-5.06 Insider Trans- Shs Float0.68M Perf Month58.15%
Income-10.11M PEG- EPS next Q- Inst Own14.45% Short Float4.91% Perf Quarter-27.21%
Sales0.00M P/S- EPS this Y65.83% Inst Trans-48.73% Short Ratio0.04 Perf Half Y-37.71%
Book/sh11.83 P/B0.47 EPS next Y31.58% ROA-42.49% Short Interest0.03M Perf Year-64.44%
Cash/sh5.60 P/C1.00 EPS next 5Y- ROE-59.91% 52W Range2.12 - 19.20 Perf YTD-68.52%
Dividend Est.- P/FCF- EPS past 5Y14.53% ROI-58.91% 52W High-65.47% Beta0.29
Dividend TTM- Quick Ratio3.30 Sales past 5Y-58.75% Gross Margin- 52W Low212.15% ATR (14)1.01
Dividend Ex-Date- Current Ratio3.30 EPS Y/Y TTM64.09% Oper. Margin- RSI (14)70.35 Volatility48.84% 20.55%
Employees24 Debt/Eq0.01 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price48.00
Option/ShortNo / No LT Debt/Eq0.01 EPS Q/Q- Payout- Rel Volume1.45 Prev Close3.04
Sales Surprise2.23% EPS Surprise-2.22% Sales Q/Q- EarningsAug 21 Avg Volume808.67K Price6.63
SMA2088.21% SMA5090.09% SMA200-15.14% Trades Volume1,174,926 Change118.29%
Date Action Analyst Rating Change Price Target Change
Sep-28-23Upgrade H.C. Wainwright Neutral → Buy $8
Sep-28-23Reiterated Maxim Group Buy $7 → $10
Jan-10-22Initiated H.C. Wainwright Buy $54
Jan-10-22Initiated Evercore ISI Outperform $17
Jan-10-22Initiated Cantor Fitzgerald Overweight $52
Jan-10-22Initiated Berenberg Buy $21
Dec-16-24 04:05PM
Dec-12-24 04:05PM
Dec-09-24 08:00AM
Dec-03-24 04:05PM
Dec-02-24 05:01PM
04:15PM Loading…
Nov-08-24 04:15PM
Nov-07-24 08:00AM
Nov-04-24 04:15PM
Oct-23-24 06:00AM
Oct-14-24 08:00AM
Oct-08-24 08:50AM
Oct-07-24 08:00AM
Oct-01-24 06:30AM
Sep-03-24 06:30AM
Jul-31-24 06:30AM
04:30PM Loading…
Jul-29-24 04:30PM
Jul-18-24 06:30AM
May-31-24 08:00AM
May-20-24 06:30AM
Mar-21-24 06:00AM
Feb-22-24 04:30PM
Feb-05-24 03:11AM
Feb-04-24 11:01AM
Jan-22-24 06:00AM
Jan-05-24 06:00AM
Dec-06-23 08:00AM
Oct-30-23 02:02PM
Oct-16-23 08:00AM
Sep-29-23 08:51AM
12:13AM
08:03AM Loading…
Sep-28-23 08:03AM
07:09AM
06:00AM
Sep-14-23 06:00AM
Aug-24-23 11:50AM
Aug-23-23 06:00AM
Jul-31-23 06:00AM
Jul-25-23 06:00AM
Jul-15-23 08:27PM
Jul-03-23 06:00AM
Jun-15-23 08:00AM
May-30-23 06:00AM
Apr-28-23 06:00AM
Apr-27-23 06:00AM
Mar-09-23 10:54AM
Mar-08-23 07:00PM
Mar-03-23 09:55AM
Feb-24-23 03:05PM
Feb-23-23 06:00AM
Feb-05-23 07:02PM
Jan-30-23 06:23PM
Dec-19-22 03:29PM
09:30AM
Dec-18-22 07:34PM
Dec-15-22 06:35PM
Dec-02-22 06:00AM
Nov-21-22 06:13PM
Nov-16-22 06:36PM
Nov-02-22 06:00AM
Oct-25-22 06:00AM
Oct-18-22 06:00AM
Oct-07-22 04:39PM
Oct-04-22 06:00AM
Sep-21-22 06:00AM
Sep-15-22 09:55AM
Aug-31-22 06:00AM
Aug-30-22 09:55AM
Aug-27-22 06:26PM
Aug-25-22 06:00AM
Aug-08-22 06:00AM
Jul-29-22 06:00AM
Jul-08-22 06:00AM
Jun-27-22 06:00AM
Jun-24-22 07:44AM
Jun-13-22 04:30PM
May-16-22 06:00AM
May-10-22 08:00AM
Feb-23-22 09:00PM
Jan-14-22 07:06AM
Jan-12-22 06:00AM
Jan-05-22 05:58PM
Jan-03-22 06:00AM
Dec-16-21 06:00AM
Bionomics Ltd. is a clinical stage biopharmaceutical company, which develops novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Its lead product candidate is BNC210. The company was founded in 1996 and is headquartered in Eastwood, Australia.